CO6862153A2 - Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) - Google Patents

Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Info

Publication number
CO6862153A2
CO6862153A2 CO14013113A CO14013113A CO6862153A2 CO 6862153 A2 CO6862153 A2 CO 6862153A2 CO 14013113 A CO14013113 A CO 14013113A CO 14013113 A CO14013113 A CO 14013113A CO 6862153 A2 CO6862153 A2 CO 6862153A2
Authority
CO
Colombia
Prior art keywords
hcv
hepatitis
infections
virus
treatment
Prior art date
Application number
CO14013113A
Other languages
English (en)
Spanish (es)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6862153(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6862153A2 publication Critical patent/CO6862153A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO14013113A 2011-08-19 2014-01-23 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) CO6862153A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
CO6862153A2 true CO6862153A2 (es) 2014-02-10

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14013113A CO6862153A2 (es) 2011-08-19 2014-01-23 Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)

Country Status (38)

Country Link
US (2) US8927593B2 (https=)
EP (2) EP2744332B1 (https=)
JP (2) JP6367712B2 (https=)
KR (1) KR101913800B1 (https=)
CN (1) CN103732065B (https=)
AR (1) AR087563A1 (https=)
AU (1) AU2012299295B2 (https=)
BR (1) BR112014002845A2 (https=)
CA (1) CA2844086A1 (https=)
CL (2) CL2014000393A1 (https=)
CO (1) CO6862153A2 (https=)
CR (1) CR20140078A (https=)
CY (1) CY1118399T1 (https=)
DK (1) DK2744332T3 (https=)
DO (1) DOP2014000034A (https=)
EA (1) EA032841B1 (https=)
ES (1) ES2611731T3 (https=)
HR (1) HRP20161743T1 (https=)
HU (1) HUE030300T2 (https=)
IL (1) IL230487B (https=)
IN (1) IN2014CN00572A (https=)
JO (1) JO3281B1 (https=)
LT (1) LT2744332T (https=)
MA (1) MA35443B1 (https=)
ME (1) ME02588B (https=)
MX (1) MX354676B (https=)
PE (1) PE20141201A1 (https=)
PH (1) PH12014500385A1 (https=)
PL (1) PL2744332T3 (https=)
PT (1) PT2744332T (https=)
RS (1) RS55462B1 (https=)
SG (1) SG10201606883QA (https=)
SI (1) SI2744332T1 (https=)
SM (2) SMT201700028T1 (https=)
TW (1) TWI538915B (https=)
UY (1) UY34274A (https=)
WO (1) WO2013028371A1 (https=)
ZA (1) ZA201401020B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
PT2744332T (pt) 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
PE20170922A1 (es) * 2014-11-10 2017-07-12 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
SG11201908012SA (en) * 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
CN117242080A (zh) * 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
BRPI0619132A2 (pt) * 2005-12-01 2011-09-13 Wyeth Corp composto métodos para inibir a replicação de um vìrus de hepatite c, para tratar ou prevenir uma infecção viral de hepatite c em um mamìfero e para inibir rna polimerase dependente do rna de hepatite c, e, composição farmacêutica
ME02188B (me) 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP2520561B1 (en) * 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP2245023B1 (en) * 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PT2744332T (pt) 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c

Also Published As

Publication number Publication date
CN103732065A (zh) 2014-04-16
IL230487A0 (en) 2014-03-31
ES2611731T3 (es) 2017-05-10
EP2744332A1 (en) 2014-06-25
KR20140054287A (ko) 2014-05-08
CR20140078A (es) 2014-03-20
EP2744332B1 (en) 2016-10-26
EA201490213A1 (ru) 2014-07-30
US9682999B2 (en) 2017-06-20
JP2017125010A (ja) 2017-07-20
AR087563A1 (es) 2014-04-03
EP2744332A4 (en) 2015-01-14
IN2014CN00572A (https=) 2015-04-03
CL2014000393A1 (es) 2014-08-01
US20150080343A1 (en) 2015-03-19
ZA201401020B (en) 2020-11-25
RS55462B1 (sr) 2017-04-28
SI2744332T1 (sl) 2017-01-31
SG10201606883QA (en) 2016-10-28
KR101913800B1 (ko) 2018-11-01
EP3199531A1 (en) 2017-08-02
JO3281B1 (ar) 2018-09-16
HRP20161743T1 (hr) 2017-02-24
SMT201700028B (it) 2017-03-08
UY34274A (es) 2013-04-05
SMT201700028T1 (it) 2017-03-08
DOP2014000034A (es) 2014-06-01
HUE030300T2 (en) 2017-04-28
MA35443B1 (fr) 2014-09-01
TWI538915B (zh) 2016-06-21
CL2017000293A1 (es) 2017-10-06
IL230487B (en) 2019-06-30
WO2013028371A1 (en) 2013-02-28
AU2012299295B2 (en) 2016-03-31
LT2744332T (lt) 2017-01-10
CY1118399T1 (el) 2017-06-28
PT2744332T (pt) 2017-01-24
PE20141201A1 (es) 2014-10-03
DK2744332T3 (en) 2017-01-16
MX2014001989A (es) 2014-02-27
US8927593B2 (en) 2015-01-06
JP6367712B2 (ja) 2018-08-01
EA032841B1 (ru) 2019-07-31
ME02588B (me) 2017-06-20
US20130237501A1 (en) 2013-09-12
PH12014500385A1 (en) 2020-06-22
CA2844086A1 (en) 2013-02-28
TW201321390A (zh) 2013-06-01
BR112014002845A2 (pt) 2017-02-21
MX354676B (es) 2018-03-15
AU2012299295A1 (en) 2014-02-20
CN103732065B (zh) 2016-10-26
JP2014527529A (ja) 2014-10-16
PL2744332T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
CO6862153A2 (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv)
SMT201600325B (it) Alifani, ciclofani, eterafani, eterofani, etero-eterafani e metalloceni sostituiti utili per il trattamento di infezioni da hcv
DK3590928T3 (da) Pyrimidinderivater til behandling af virusinfektioner
CL2015000482A1 (es) Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
IL232046A0 (en) Purine derivatives for the treatment of viral infections
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
HUE057928T2 (hu) Coronaviridae családba tartozó vírus okozta fertõzések kezelésére szolgáló eljárások
CL2015000925A1 (es) Compuestos derivados de heterociclos nitrogenados; composicion farmaceutica; un metodo para tratar infecciones viricas provocadas por virus sincicial respiratorio (vsr)
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
ZA201501018B (en) Compounds for the treatment of paramoxyvirus viral infections
DK2958900T3 (da) 2-aminopyrimidinderivater til behandling af virusinfektioner
CO6821947A2 (es) Inhibidores del virus de la hepatitis c
BR112013012998A2 (pt) compostos para tratar infecções por vírus sincicial respiratório
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
DK2939665T3 (da) Farmaceutisk sammensætning til behandling af hiv-infektioner
EP2756102A4 (en) DETECTION OF VIRAL INFECTION
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
EP2900656A4 (en) SPIRO CYCLE COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS (HCV)
DK2723336T3 (da) Sammensætninger til behandling af fragilt X-syndrom
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
BR112013011405A2 (pt) composição farmacêutica para tratar infecções por hcv
ZA201306342B (en) The treatment of viral infections
BR112013025021A2 (pt) alisporivir para tratar infecções por vírus de hepatite c.

Legal Events

Date Code Title Description
FG Application granted